Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles

Vaccine

Volumn 17, Issue 23-24, 1999, Pages 3007-3019

  Frey, Andreas ^a,b   Mantis, Nicholas ^a,b   Kozlowski, Pamela A ^a,b   Quayle, Alison J ^b,c   Bajardi, Adriana ^a,b   Perdomo, Juana J ^a   Robey, Frank A ^d   Neutra, Marian R ^a,b  

^a Enders 1220 Children's H   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d Gene Therapy and Therapeutics Branch   (United States)

Author keywords

Adjuvant; Antibodies; Vaccine

Indexed keywords

ALUMINUM OXIDE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; NANOPARTICLE; PEPTIDE; POLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONJUGATION; DRUG EFFICACY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHILICITY; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VIRUS RECOMBINANT;

AIDS VACCINES; ALUMINUM OXIDE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, CD4; FEMALE; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; INTESTINAL MUCOSA; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PARTICLE SIZE; PEPTIDE FRAGMENTS; T-LYMPHOCYTES;

EID: 0033529514     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00163-2     Document Type: Article

References (47)

1. Burton DR A vaccine for HIV type 1: The antibody perspective. In: Proceedings of the National Academy of Sciences USA, 1997. 94. p. 10018-10023.
2. Moore J.P., Sattentau Q.J., Wyatt R., Sodroski J. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. Journal of Virology. 68:1994;469-484.
3. Lasky L.A., Nakamura G., Smith D.H., Fennie C., Shimasaki C., Patzer E., Berman P., Gregory T., Capon D.J. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell. 50:1987;975-985.
4. Cordonnier A., Montagnier L., Emerman M. Single amino-acid changes in HIV envelope affect viral tropism and receptor binding. Nature [London]. 340:1989;571-574.
5. Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, Berzofsky JA Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. In: Proceedings of the National Academy of Sciences USA, 1987. 84. p. 4249-4253.
6. Berzofsky J.A., Pendleton C.D., Clerici M., Ahlers J., Lucey D.R., Putney S.D., Shearer G.M. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types. Journal of Clinical Investigation. 88:1991;876-884.
7. Clerici M., Stocks N.I., Zajac R.A., Boswell R.N., Bernstein D.C., Mann D.L., Shearer G.M., Berzofsky J.A. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature [London]. 339:1989;383-385.
8. Sun N-C., Ho D.D., Sun C.R.Y., Liou R-S., Gordon W., Fung M.S.C., Li X-L., Ting R.C., Lee T-H., Chang N.T., Chang T-W. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. Journal of Virology. 63:1989;3579-3585.
9. Nakamura G.R., Byrn R., Wilkes D.M., Fox J.A., Hobbs M.R., Hastings R., Wessling H.C., Norcross M.A., Fendly B.M., Berman P.W. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1. Journal of Virology. 6:1993;6179-6191.
10. Palker T.J., Matthews T.J., Langlois A., Tanner M.E., Martin M.E., Scearce R.M., Kim J.E., Berzofsky J.A., Bolognesi D.P., Haynes B.F. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. Journal of Immunology. 142:1989;3612-3619.
11. Hart M.K., Palker T.J., Matthews T.J., Langlois A.J., Lerche N.W., Martin M.E., Scearce R.M., McDanal C., Bolognesi D.P., Haynes B.F. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. Journal of Immunology. 145:1990;2677-2685.
12. Nardelli B., Lu Y-A., Shiu D.R., Delpierre-Defoort C., Profy A.T., Tam J.P. A chemically defined synthetic vaccine model for HIV-1. Journal of Immunology. 148:1992;914-920.
13. Ahlers J.D., Pendleton C.D., Dunlop N., Minassian A., Nara P.L., Berzofsky J.A. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations. Journal of Immunology. 150:1993;5647-5665.
14. Bukawa H., Sekigawa K-I., Hamajima K., Fukushima J., Yamada Y., Kiyono H., Okuda K. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate. Nature Medicine. 1:1995;681-685.
15. Staats H.F., Nichols W.G., Palker T.J. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). Journal of Immunology. 157:1996;462-472.
16. Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. In: Proceedings of the National Academy of Sciences USA 1997, 1997. 94. p. 10856-10861.
17. Robey F.A., Kelson-Harris T., Roller P.P., Robert-Guroff M.A. A helical epitope in the C4 domain of HIV glycoprotein 120. Journal of Biological Chemistry. 270:1995;23918-23921.
18. Reed J., Kinzel V. A conformational switch is associated with receptor affinity in peptides derived from the CD4-binding domain of gp120 from HIV-1. Biochemistry. 30:1991;4521-4528.
19. von Stosch Graf A., Kinzel V., Pipkorn R., Reed J. Investigation of the structural components governing the polarity-dependent refolding of a CD4-binding peptide from gp120. Journal of Molecular Biology. 250:1995;507-513.
20. Robey F.A., Harris-Kelson T., Robert-Guroff M., Batinic D., Ivanov B., Lewis M.S., Roller P.P. A synthetic conformational epitope from the C4 domain of HIV gp120 that binds CD4. Journal of Biological Chemistry. 271:1996;17990-17995.
21. Scibienski R.J. Denaturation of lysozyme by Freund's complete adjuvant. Journal of Immunology. 111:1973;114-120.
22. Gupta R.K., Relyveld E.H., Lindblad E.B., Bizzini B., Ben-Efraim S., Gupta C.K. Adjuvants - a balance between toxicity and adjuvanticity. Vaccine. 11:1993;293-306.
23. Weissburg R.P., Berman P.W., Cleland J.L., Eastman D., Farina F., Frie S., Lim A., Mordenti J., Peterson M.R., Yim K., Powell M.F. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharmaceutical Research. 12:1995;1439-1446.
24. MN gp120. Bioconjugate Chemistry. 8:1997;424-433.
25. Robey F.A. Bromoacetylated synthetic peptides: starting materials for cyclic peptides, peptomers and peptide conjugates. Pennington M., Dunn B. Methods in molecular biology. vol. vol. 35:1994;73 Humana Press, Totowa, NJ, Inc.
26. Haneberg B., Kendall D., Amerongen H.M., Apter F.M., Kraehenbuhl J-P., Neutra M.R. Induction of specific immunoglobulin A in the small intestine, colon-rectum, and vagina measured by a new method for collection of secretions from local mucosal surfaces. Infection and Immunity. 62:1994;15-23.
27. Kozlowski P.A., Chen D.C., Eldridge J.H., Jackson S. Contrasting IgA and IgG neutralization capacities and responses to HIV type 1 gp120 V3 loop in HIV-infected individuals. AIDS Research and Human Retroviruses. 10:1994;813-822.
28. Weltzin R., Lucia-Jandris P., Michetti P., Fields B.N., Kraehenbuhl J-P., Neutra M.R. Binding and transepithelial transport of immunoglobulins by intestinal M cells: demonstration using monoclonal IgA antibodies against enteric viral proteins. Journal of Cell Biology. 108:1989;1673-1685.
29. Tijssen P. Practice and theory of immunoassays. 1985;385-421 Elsevier Science Publishers, Amsterdam, The Netherlands.
30. Gurgo C., Guo H-G., Franchini G., Aldovini A., Collalti E., Farrell K., Wong-Staal F., Gallo R.C., Reitz M.S. Jr. Envelope sequences of two new United States HIV-1 isolates. Virology. 164:1988;531-536.
31. Xu-Amano J., Kiyono H., Jackson R.J., Staats H.F., Fujihashi K., Burrows P.D., Elson C.O., Pillai S., McGhee J.R. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. Journal of Experimental Medicine. 178:1993;1309-1320.
32. Mosmann T.R., Coffman R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology. 7:1989;145-173.
33. Hsieh C-S., Macatonia S.E., O'Garra A., Murphy K.M. T helper cell genetic background determines default T helper phenotype development in vitro. Journal of Experimental Medicine. 181:1995;713-721.
34. Tam JP Synthetic peptide vaccine design: Synthesis and properties of a high-density multiple antigenic peptide system. In: Proceedings of the National Academy of Sciences USA, 1988. 85. p. 5409-5413.
35. b-restricted: possible implications for malaria vaccines. Journal of Immunology. 137:1986;2952-2955.
36. Borras-Cuesta F., Fedon Y., Petit-Camurdan A. Enhancement of peptide immunogenicity by linear polymerization. European Journal of Immunology. 18:1988;199-202.
37. Hillman K., Shapira-Nahor O., Blackburn R., Hernandez D., Golding H. A polymer containing a repeating peptide sequence can stimulate T-cell-independent IgG antibody production in vivo. Cellular Immunology. 134:1991;1-13.
38. Harms J., Mausle E. Tissue reaction to ceramic implant material. Journal of Biomedical Materials Research. 13:1979;67-87.
39. Fevrier M., Birrien J.L., Leclerc C., Chedid L., Liacopoulos P. The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. European Journal of Immunology. 8:1978;558-562.
40. Fraser-Smith E.B., Waters R.V., Matthews T.R. Correlation between in vivo anti-Pseudomonas and anti-Candida activities and clearance of carbon by the reticuloendothelial system for various muramyl dipeptide analogs, using normal and immunosuppressed mice. Infection and Immunity. 35:1982;105-110.
41. Neutra M.R., Frey A., Kraehenbuhl J-P. Epithelial M cells: gateways for mucosal infection and immunization. Cell. 86:1996;345-348.
42. Neutra M.R., Pringault E., Kraehenbuhl J-P. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annual Review of Immunology. 14:1996;275-300.
43. Elson C.O., Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. Journal of Immunology. 133:1984;2892-2897.
44. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 59:1986;301-308.
45. Frey A., Giannasca K.T., Weltzin R., Giannasca P.J., Reggio H., Lencer W.I., Neutra M.R. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. Journal of Experimental Medicine. 184:1996;1045-1059.
46. Ugolev A.M., DeLaey P. Membrane digestion. A concept of enzymatic hydrolysis on cell membranes. Biochemica Biophysica Acta. 300:1973;105-128.
47. Waring R.H. Variation in human metabolism of S-carboxymethylcysteine. European Journal of Drug Metabolism and Pharmacokinetics. 5:1980;49-52.